Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.43 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.43 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16456582 | 0.83 | MAPK14 (0.43) | LMNAMAPK14TRPV1KDM4EALDH1A1 | |
| SCHEMBL14360820 | 0.82 | LMNA (0.55) | LMNAGAATRPV1USP2KDM4E | |
| SCHEMBL8261109 | 0.82 | LMNA (0.51) | LMNAMAPK14GAAUSP2KDM4E | |
| SCHEMBL8261714 | 0.82 | LMNA (0.54) | LMNAGAAUSP2KDM4EALDH1A1 | |
| SCHEMBL8263238 | 0.80 | LMNA (0.51) | LMNAMAPK14GAAUSP2KDM4E | |
| SCHEMBL8297610 | 0.78 | POLB (0.55) | LMNAGAAKDM4EALDH1A1CRACR2A | |
| SCHEMBL4764906 | 0.78 | IL2 (0.60) | MAPK14TRPV1 | |
| SCHEMBL15463135 | 0.77 | MAPK14 (0.49) | MAPK14TRPV1ALDH1A1 | |
| SCHEMBL7972108 | 0.76 | LMNA (0.84) | LMNAGAAUSP2KDM4EALDH1A1 | |
| SCHEMBL10218228 | 0.75 | LMNA (0.48) | LMNAMAPK14GAAUSP2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846372-B1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20140039009-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20120225883-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-09-06 | — | — | US | disclosed |
| US-8202999-B2 | biphenyl and pyridylphenyl derivatives such as 2,6-Difluoro-N-[2'-methyl-5'-(pyridine-3-yl)-biphenyl-4-yl]-benzamide, used as immunosuppressants for the treatmet or prevent allergies, inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202999-B2 | biphenyl and pyridylphenyl derivatives such as 2,6-Difluoro-N-[2'-methyl-5'-(pyridine-3-yl)-biphenyl-4-yl]-benzamide, used as immunosuppressants for the treatmet or prevent allergies, inflammatory and immune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2012-06-19 | — | — | US | disclosed |
| WO-2006083477-A2 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225883-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR8, CXCR2 | LMNA 3080/4885MAPK14 3191/4885GAA 979/4885 |
| US-20140039009-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR8, CXCR2 | LMNA 3080/4885MAPK14 3191/4885GAA 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.